LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: May 21, 2024
UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2024.
Read more at globenewswire.comNASDAQ:LVTX (6/17/2025, 8:00:01 PM)
1.3
+0.01 (+0.78%)
Find more stocks in the Stock Screener
